China SXT Pharmaceuticals (SXTC) Announces Share Consolidation

China SXT Pharmaceutics, Inc. (Nasdaq: SXTC) (the “Company” or “SXTC”), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces (“TCMPs”), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements (“TCMHS”), today announced that it will effect a share consolidation of its ordinary shares at a ratio of 1-for-8, effective on February 25, 2025 (the “Share Consolidation”). The Company’s ordinary shares are expected to begin trading on a post-consolidation basis at the open of the market session on February 25, 2025. Upon the market opening on February 25, 2025, the Company’s ordinary shares will continue to be traded on The Nasdaq Stock Market under the symbol “SXTC” with the new CUSIP number G2161P157.

The Company’s Board of Directors approved the afore-mentioned Share Consolidation so as to regain compliance with the minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Stock Market (the “Minimum Bid Price Requirement”). In order to maintain the Company’s listing on the Nasdaq Stock Market, the Company’s ordinary shares must have a closing bid price of $1.00 or more for a minimum of ten consecutive trading days by April 1, 2025. There can be no assurance that following the Share Consolidation, the Company’s ordinary shares will remain above $1.00 per share minimum for the requisite period to regain listing compliance. In the event that the Company does not regain compliance with the Minimum Bid Price Requirement, its securities may be subject to delisting from the Nasdaq Stock Market which, in turn, will result in significant adverse effect on the value and liquidity of the Company’s securities.

As a result of the Share Consolidation, every eight (8) shares of the Company’s ordinary shares will be automatically consolidated into one ordinary share. No fractional shares will be issued in connection with the Share Consolidation, and in the event that a shareholder would otherwise be entitled to receive a fractional share upon the Share Consolidation, the number of shares to be received by such shareholder will be rounded up to one ordinary share in lieu of the fractional share that would have resulted from the Share Consolidation. All outstanding stock options, warrants and other rights to purchase the Company's ordinary shares will be adjusted proportionately as a result of the Share Consolidation.

Upon the effectuation of the Share Consolidation, shareholders holding shares through a bank, broker or other nominee will have their shares automatically adjusted to reflect the share consolidation. Beneficial holders may contact their bank, broker or nominee for more information. Please direct any questions to your broker or the Company's transfer agent, Transhare Corporation, by calling +1 303-662-1122.

You May Also Be Interested In

• Hanmi Pharm licenses obesity drug to Genentech in $2.3B deal
• Cytek faces $56M damages award in Beckman Coulter patent case
• loanDepot receives NYSE non-compliance notice over stock price